Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Dec '22	Dec '23
account payables	1.72M -	1.12M 35%
accumulated other comprehensive income loss	-127K -	2K 101.57%
cash and cash equivalents	25.82M -	46.11M 78.61%
cash and short term investments	93.07M -	49.06M 47.28%
common stock	1K -	1K 0%
deferred revenue	-1.72M -	-1.12M 35%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	469K -	30.86M 6,479.96%
long term investments	1.14M -	1.02M 10.02%
net debt	-24.04M -	-13.53M 43.72%
net receivables	500K -	614K 22.80%
other assets		1 -
other current assets	8.98M -	3.68M 59.06%
other current liabilities	12.04M -	18.03M 49.75%
other liabilities
other non current assets		7.00K -
other non current liabilities	4.12M -	1.77M 56.97%
othertotal stockholders equity	14.21M -	25.05M 76.33%
preferred stock	285.47M -	375.37M 31.49%
property plant equipment net	4.47M -	35.22M 687.13%
retained earnings	-209.32M -	-364.32M 74.04%
short term debt	1.31M -	1.72M 31.30%
short term investments	67.25M -	2.96M 95.60%
tax assets
tax payables
total assets	108.17M -	89.61M 17.15%
total current assets	102.56M -	53.36M 47.97%
total current liabilities	13.35M -	20.87M 56.31%
total debt	1.78M -	32.58M 1,731.37%
total investments	68.39M -	3.98M 94.18%
total liabilities	17.94M -	53.50M 198.28%
total liabilities and stockholders equity	108.17M -	89.61M 17.15%
total non current assets	5.61M -	36.25M 545.91%
total non current liabilities	4.58M -	32.63M 611.69%
total stockholders equity	90.23M -	36.11M 59.98%

ALMS

COM:ALUMIS

Alumis

Last Close

9.44

22/11 21:00

Market Cap

668.34M

Beta: -

Volume Today

115.52K

Avg: -

Preview